HLX48

Phase 1Small molecule

Shanghai Henlius Biotech

HLX48 is one of 33 small molecule programs targeting Advanced/Metastatic Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced/metastatic Solid TumorsRecruiting

Advanced/metastatic Solid TumorsPhase 1

Recruiting

Competition

Competitive Landscape

50 competitors in Advanced/metastatic Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

8 2

Fludara

Sanofi

Phase 2

2 3

Tagrisso

AstraZeneca

Phase 2

1 4

Xtandi

Astellas

Phase 2

1 5

Zytiga

Johnson & Johnson

Phase 2

1 6

Cytoxan

BBaxter Healthcare Corporation

Phase 2

3 7

Herceptin

OOrganon and Co

Phase 2

1 8

Sporanox

SSebela Pharmaceuticals Development LLC

Phase 2

1 9

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 2

2 10

BNT327

BioNTech

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Advanced/metastatic Solid Tumors

NCT07473726

Clinical

Trials by Indication[1]

Advanced/Metastatic Solid Tumors1 trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX48 (EGFR/c-MET Bispecific Antibody-Drug Conjugate) in Participants With Advanced/Metastatic Solid Tumors

Recruiting· Shanghai Henlius Biotech logo

Shanghai Henlius Biotech·Phase 1·NCT07473726·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HLX48. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HLX48 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HLX48. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Henlius Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Shanghai Henlius Biotech

HLX48

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Advanced/Metastatic Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News